management of osteoporosis final
DESCRIPTION
TRANSCRIPT
![Page 1: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/1.jpg)
04/08/2304/08/23 11
![Page 2: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/2.jpg)
OsteoporosisOsteoporosisDefinitionDefinition
• Systemic skeletal disease.
• Low bone mass.• Microarchitectural
deterioration of bone tissue.
• Damage accumulation• Low strength
• Increase in bone fragility.• Susceptibility to fracture.• Hip,spine,wrist ,ankle ,hu
merus
04/08/2304/08/23 22
![Page 3: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/3.jpg)
OsteoporosisOsteoporosis
• A major health problem.• • Consequences include - illness, pain,
functional limitations, reduced quality of life, loss of independence, inability to work and even death.
• 1 out of 3 women (33.3%) &1 out of 8 men (12.5%) suffer from osteoporosis related fracture in lifetime
• Grave disease, highly under diagnosed and under treated.04/08/2304/08/23 33
![Page 4: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/4.jpg)
Diagnosis: x-ray -NoDiagnosis: x-ray -No
• Insensitive • Apparent only after 50 -70 %
reduction in bone mass
• High radiation
04/08/2304/08/23 44
![Page 5: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/5.jpg)
Bone Mineral DensityBone Mineral Density
• DEXA :DUAL Energy X-ray Absorptiometry-Gold standard
• Single X-ray Absorptiometry /
Quantitative CT
• ULTRASONIC BONE DENSITOMETER
– Lower accuracy– No ionizing
radiation
GOLD STANDARD04/08/2304/08/23 55
![Page 6: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/6.jpg)
WHO ClassificationWHO ClassificationNormal : BMD within 1 to -1 SDNormal : BMD within 1 to -1 SD
Osteopenia :BMD -1 - 2.5 SD
Osteoporosis :BMD -2.5 SD or more
04/08/2304/08/23 66
![Page 7: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/7.jpg)
MANAGEMENT• Change of life style most
important
• Regular exercise must
• Stop smoking and alcohol intake
• If on steroids / phenytoin taken for long then alendronate must be given
• Adequate exposure to sun
04/08/2304/08/23 77
![Page 8: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/8.jpg)
CALCIUM AND VITAMIN CALCIUM AND VITAMIN DD• Calcium and Vit D are main stay.• Calcium 1000 mg /day with SERM/Alendronate/HT• • 1500 mg /day if no therapy
Calcium carbonate does not cause renal calculi
• Vitamin D :Dose 400 IU < 70 yrs 700 – 1000 IU > 70 yrs
CALCITRIOL • watch for Hypercalcemia / Hypercalciurea on long
term use • No extra benefit for idiopathic postmenopausal
osteoporosis
04/08/2304/08/23 88
![Page 9: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/9.jpg)
Updated National Osteoporosis Foundation Updated National Osteoporosis Foundation (NOF) guidelines 2008(NOF) guidelines 2008
• After introduction of FRAX® pharmacologic treatment is recommended for postmenopausal women over age 50 with
• A hip or vertebral (clinical or morphometric) fracture. • T-score ≤ –2.5 at the femoral neck or spine after appropriate
evaluation to exclude secondary causes. • Low bone mass (T-score between –1.0 and –2.5 at the femoral neck
or spine) and a 10-year probability of a hip fracture ≥ 3% or a 10-year probability of any major osteoporosis-related fracture ≥ 20% based on US-adapted WHO absolute fracture risk model (FRAX®).
• NOF. Clinician’s Guide. 2008;1-36.
04/08/2304/08/23 99
![Page 10: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/10.jpg)
Drugs available and on horizonsDrugs available and on horizonsAntiresoptives- Inhibit osteoclastic activity
• HT
• SERMS
• Bishphosphonates
• New drugs in pipeline
Anabolic stimulate bone fromation
• PTH
• Strontium
• Flouride
• IGF-1
• PREVOS / SOTI / TROPOS
• Tibolone
• Statins04/08/2304/08/23 1010
![Page 11: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/11.jpg)
ESTROGENESTROGEN
• Women’s Health Initiative (WHI)
– 16,608 postmenopausal women
– E-P combination to assess CHD / breast CA
– RR spine and hip fractures = 0.66
• Heart and Estrogen/progestin Replacement Study (HERS)-No reduction in fracture incidence
04/08/2304/08/23 1111
![Page 12: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/12.jpg)
HT HT
Indicated :
• For relief of vasomotor symptoms
• Urogenital symptoms
• Not for prevention or treatment of osteoporosis.
04/08/2304/08/23 1212
![Page 13: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/13.jpg)
SERMS- RALOXIFENE (EVISTA®)SERMS- RALOXIFENE (EVISTA®)
Raloxifene• Non-steroidal benzothiopene – binds Estrogen receptor, Inhibits bone
resorption without stimulating endometrium
• Multiple Outcomes of Raloxifene Evaluation (MORE)
- Studied 60 mg and 120 mg doses on patients with and without VCF(vertebral clinical fracture)
- 2.6% BMD compared to placebo
- 30% (prior VCF) and 50% (no prior VCF) reduction in VCF
- RR of DVT = 3
- Significant reduction in incidence of breast CA
04/08/2304/08/23 1313
![Page 14: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/14.jpg)
SERM- Bazedoxifene SERM- Bazedoxifene
• Bazedoxifene binds to both ERs with high affinity
• Agonist on skeletal tissue, with bone turnover reduced by 20–25% with doses of 20 or 40 mg daily
• Antagonist on breast tissue and uterine tissue
• Side effects are hot flashes
04/08/2304/08/23 1414
![Page 15: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/15.jpg)
Selective Estrogen Receptor-ß Agonist, MF-101( 22 chinese herbal medicines)
• MF-101-isolated active compounds, liquiritigen and chalcone, demonstrated selectivity for ER-ß
• No effect on growth of breast cancer cells
• No stimulation endometrium in Phase II trial
• Effective in reducing the frequency and severity of hot flashes in postmenopausal women.
• In order to confirm the safety and efficacy of MF-101, larger Phase III trials have been planned for 2009.
04/08/2304/08/23 1515
![Page 16: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/16.jpg)
TSEC & SERMSTSEC & SERMS
• An appealing alternative strategy is the use of a tissue-specific estrogen complex (TSEC). TSECs combine an estrogen and a SERM, taking advantage of the tissue-specific anti-estrogenic properties of the SERM in order to counteract the effects of estrogen on the uterus and breast. This combination, therefore, requires no progestogen.
• Pinkerton JV, Utian W, Constantine G, Olivier MD, Pickar J. SMART-2: A phase III study of the efficacy and safety of bazedoxifene/conjugated estrogens for treatment of menopausal vasomotor symptoms. Proceedings and abstract. Menopause. 2007;14(Suppl. 2):1081.
04/08/2304/08/23 1616
![Page 17: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/17.jpg)
04/08/2304/08/23 1717
![Page 18: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/18.jpg)
BISPHOSPHONATESBISPHOSPHONATES
Adverse effect• Poor intestinal absorption
• N2 – containing
• GI upset
• Oesophagitis
• Patient should remain upright ,take with a glass of water
04/08/2304/08/23 1818
![Page 19: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/19.jpg)
Alendronate (Bishphonate)Alendronate (Bishphonate)• Non hormonal
• FDA approved
• For prevention as well as treatment
• Increases BMD by 8.8% in lumbar spine and 6% in fracture NOF
• 48% reduction in # NOF and spine fractures
• Can be given for 5- 10 yrs or treatment free holidays can be givne.
04/08/2304/08/23 1919
![Page 20: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/20.jpg)
DOSE:daily or weekly
Except – very elderly and poor renal function
PREVENTION :5mg per day,35 mg /weekTreatment : 10 mg/day , 70 mg/week
CARE• Empty stomach consumption
• Calcium to be taken after 4 hrs
• Longest duration tried – upto 5 yrs
04/08/2304/08/23 2020
![Page 21: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/21.jpg)
RISEDRONATE (ACTONEL®)RISEDRONATE (ACTONEL®)The Vertebral Efficacy with Risedronate
Therapy (VERT) Study
• North American and Multinational Arms
• Randomized, double-blind, placebo-controlled study of 2458 postmenopausal women c >1 VCF
• Treatment with 5mg/day for 3 years:
– incidence of new VCF by 41%
- BMD 5.4% vs. 1/1% (placebo)04/08/2304/08/23 2121
![Page 22: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/22.jpg)
RISEDRONATERISEDRONATE • Not recommended in patients with renal impairment
• Contra Indications
•Hypocalcaemia
•Hypersensitivity
•Inability to sit upright for 30 min.
• Side Effects
• Dysphagia
• Esophagitis
• Esophageal
• Gastric ulcer
04/08/2304/08/23 2222
![Page 23: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/23.jpg)
CALCITONINCALCITONIN• 32 amino acid polypeptide produced by the parafollicular “C” cells of the
thyroid in response in plasma Calcium
• Binds to osteoclast cell receptor (-) effect)
• FDA approved for treatment but NOT prevention of
postmenopausal osteoporosis
• Women > 5yrs after menopause
• Consider in women with estrogen-dependent neoplasm, H/o DVT, renal insufficiency, or active GI pathology
• Nasal spray (preferred) and injectable forms• Miacalcin®: 200 IU qd
04/08/2304/08/23 2323
![Page 24: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/24.jpg)
CALCITONINCALCITONIN
Prevent Recurrence of Osteoporotic Fracture Study (PROOF)
• 5-yr, multicenter, double-blind, randomized
study – 1255 patients
• 817 pts c 1-5 previous VCF• Nasal spray salmon calcitonin (100, 200, 400 IU)
• 36% reduction in VCF (33% for entire group)
• Lumbar BMD 1.2% during only 1st yr
04/08/2304/08/23 2424
![Page 25: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/25.jpg)
CALCITONINCALCITONIN• Analgesic Effects
• Analgesic for acute and chronic pain of VCF
• Apparent by = 1 week
• Mechanism likely a central effect (hypothalamus,PAG, dorsal horn)
• Side Effects• Minimal: rhinitis, back/joint pain, HA• Resistance• Antibodies in 20% PROOF patients
04/08/2304/08/23 2525
![Page 26: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/26.jpg)
CALCITONINCALCITONIN
INJECTABLE – 100 IU/day s/c BIOCALCIN NASAL SPRAY 200 IU /day MIACALCIN
• Inhibits osteoclast
• Increases BMD by inhibiting osteoclast, decrease vertebral fractures
• Good for pain in spinal fractures
04/08/2304/08/23 2626
![Page 27: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/27.jpg)
ANABOLIC AGENTSANABOLIC AGENTS• PTH
• Fluoride
• IGF-1
• Strontium
• PREVOS / SOTI / TROPOS
• Tibolone
• Statins04/08/2304/08/23 2727
![Page 28: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/28.jpg)
PTHPTH• Forteo
– Teriparatide = generic name• Synthetic teriparatide has been used in many clinical trials• Forteo is the recombinant DNA PTH 1-34 manufactured by
Eli Lilly• Genetically engineered fragment of native PTH (84 amino
acids)• FDA approved in US and Europe
• 24 month treatment period– $ 600/month• A Recombinant DNA prep with all 84 amino acids (Preos) is
in clinical trials
04/08/2304/08/23 2828
![Page 29: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/29.jpg)
PTHPTH (Forteo)(Forteo)Neer et al. (2001) NEJM 344(19), 1434-1441Neer et al. (2001) NEJM 344(19), 1434-1441
• Landmark Placebo controlled, randomized trial of 1637 postmenopausal women with prior vertebral fracture
• 20µg vs 40µg Forteo
• RR VCF = 0.35 for 20µg dose and 0.31 for 40µg
• Lumbar spine BMD - 9%
• Femoral neck BMD - 3%
• Distal radius BMD - 2%
04/08/2304/08/23 2929
![Page 30: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/30.jpg)
PTH (Forteo)PTH (Forteo)• Side Effects• Hypercalcemia (rare clinical significance)• Leg cramps, dizziness• Dose dependent increase in osteosarcoma in rats• None in 2000 Forteo patients
• Contraindications• Patients with open epiphysis• Paget disease• Prior skeletal malignancy• Metabolic bone diseases• Pre-existing hypercalcemia (Primary hyperparathyroidism)
04/08/2304/08/23 3030
![Page 31: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/31.jpg)
New Drug DenosumabNew Drug Denosumab
• Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor- kB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption , and increasing bone density
04/08/2304/08/23 3131
![Page 32: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/32.jpg)
Dose of DenosumabDose of Denosumab
• Denosumab given 60 mg subcutaneously twice yearly for 36 months associated with reduced risk of vertebral, nonvertebral and hip fractures in postmenopausal women with osteoporosis
04/08/2304/08/23 3232
![Page 33: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/33.jpg)
ORTHOSISORTHOSIS• (A) The posture training support vest
contains 680 g (1.5 pound) weights to remind the patient to extend their thoracic spine.
• (B) The Spinomed® brace consists of a back pad and strap system to strengthen the trunk muscle and improve posture.
• (C) Hip protectors contain padding over the trochanters to help absorb the impact of a fall
• Sinaki M et al. (2002) Stronger back muscles reduce the incidence of vertebral fractures: a prospective 10 year follow-up of postmenopausal women. Bone 30: 836–841
04/08/2304/08/23 dr.maninder AICOG2009dr.maninder AICOG20093333
Improved back extensor strength correlate with decreased kyphosis and diminished vertebral fracture risk.
Hip protectors don’t reduce incidence of hip fracturesVan Schoor NM, Smit JH, Twisk JWR, et al. Prevention of hip fractures by external hip protectors: a randomized controlled trial. JAMA. 2003;289(15):1957–1962
![Page 34: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/34.jpg)
FALL PREVENTION FALL PREVENTION
• Frailty and associated deconditioning;
• Poor visual acuity;
• Gait disturbances;
• Impaired hearing;
• Use of medications with that are sedating or compromise balance; and
• Dangers in the environment, including loose rugs, lack of hand rails in the bathroom, etc.
04/08/2304/08/23 dr.maninder AICOG2009dr.maninder AICOG20093434
![Page 35: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/35.jpg)
To Summarise”Drugs for prevention&treatment” To Summarise”Drugs for prevention&treatment” • Estrogens/only in early menopause and premature menopause
• Alendronate- 5-10mg daily,35-70 mg /weekly• Risendronate daily2.5-5mg/day or weekly• Ibandronate 150 mg monthly,3 monthly• Zolendronic acid yearly 3mg I/V over 10-15min • Calcitonin nasal spray 200 IU daily• Raloxifene 60mg daily,lipid friendly ,lowers LDL• Teriparatide s/c20 – 40 µg/day .can be given*18-24months• Strontium ranelate 2 gm/day• Osteoprotegrin 3 mg/kg s/c N-Telopeptide decreases in 5day• Tibolone(not FDA approved for osteoporosis)• Progesterone and growth hormones are being studied&also flourides
• ePocrates. Computerized pharmacology and prescribing reference. updated daily. Available at: ePocrates.com Accessed September 19, 2008.
04/08/2304/08/23 dr.maninder AICOG2009dr.maninder AICOG20093535
![Page 36: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/36.jpg)
Raloxifene
PTH
CalcitoninHRTHRT
HRTHRT
During Hot Flashes
Post Vasomotor SymptomsPre fracture
Post Fracture
Risk of Fracture
AGE
At Risk/Osteopenia Osteoporosis Severe OsteoporosisSTAGE
LowerHigher-2.5BMD (T-score)
Bisphosphonates
Osteoporosis Therapy AlgorithmOsteoporosis Therapy AlgorithmPostmenopausal WomenPostmenopausal Women
04/08/2304/08/23 3636
![Page 37: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/37.jpg)
OSTEOPOROSISOSTEOPOROSIS HIP FRACTURES HIP FRACTURES
04/08/2304/08/23 3737
![Page 38: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/38.jpg)
OSTEOPOROSISOSTEOPOROSIS HIP FRACTURES HIP FRACTURES
• Operate Early
• High mortality & morbidity by non-operative
Treatment
04/08/2304/08/23 3838
![Page 39: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/39.jpg)
OSTEOPOROSISOSTEOPOROSIS SPINE FRACTURES SPINE FRACTURES
• Acute # :
• NSAIDS & rest• Calcitonin• Orthosis• Reduction in rate of bone loss• Reduction of rate of #
04/08/2304/08/23 3939
![Page 40: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/40.jpg)
04/08/2304/08/23 4040
![Page 41: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/41.jpg)
04/08/2304/08/23 4141
![Page 42: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/42.jpg)
Final Word Final Word
• The real need in osteoporosis treatment is for additional anabolic agents
• "Our success or failure in combating osteoporosis increasingly depends not so much on the drugs available to us but rather on our ability to engage our patients and ensure that they take the medications we prescribe
04/08/2304/08/23 4242
![Page 43: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/43.jpg)
Final Message Final Message
ADD LIFE TOYEARS,
NOT YEARS TO LIFE.
“AGE GRACEFULLY”
04/08/2304/08/23 4343
![Page 44: Management of osteoporosis final](https://reader033.vdocuments.us/reader033/viewer/2022051322/54532f29af7959c07f8b6c10/html5/thumbnails/44.jpg)
ACKNOWLEDGEMENTACKNOWLEDGEMENT
• Dr.Sonal Bathla• MD,FICOG,FICMCH• SANT PARMANAND HOSPITAL
Dr. Shekhar Agarwal
Executive Director ,HOD of Orthopaedics
SANT PARMANAND HOSPITAL
Dr.Maninder Ahuja Chairperson Geriatric Gynecology Committee FOGSI
04/08/2304/08/23 4444